Dr. Härfstrand is Chairman of Härfstrand Consulting AG, which he founded in 2010. Dr. Härfstrand also served as Chief Executive Officer of BBB Therapeutics BV from 2014 to 2015. Prior to that, he was President and Chief Executive Officer Europe of Makhteshim Agan Industries Ltd. from 2013 to 2014; President and Chief Executive Officer of Humabs BioMed SA from 2011 to 2012; and Chief Executive Officer of Nitec Pharma AG from 2007 to 2010. Dr. Härfstrand currently serves as chairman of Oasmia Pharmaceuticals AB and as a chairman of Diurnal Group plc, and served as a director of Karolinska Development AB from 2017 to 2019. He also served in various executive and management roles at Serono, Pfizer and Pharmacia, and in non-executive roles on a number of Supervisory Boards in Europe. Dr. Härfstrand earned his M.D. and Ph.D. in neuropharmacology endocrinology from Karolinska Institute in Sweden. He has served on our Board since 2015.